Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Maria D Lopez, MBA
CONTACT
Adelaide A Hebert, MD
CONTACT
Lead
Miller Biosciences LLC
Protocol TCAAP-PH will investigate TCA use in participants with palmar hyperhidrosis. This is a pilot, open-label, single site study designed to evaluate the safety and efficacy of TCA in participants 18 years of age and older. The study will have a maximum study duration of 4 weeks. This includes screening/baseline, a 1-week treatment period, and a 4 week follow up phone call and exit survey. A total of approximately 30 participants will be enrolled in this study. At the inception of the trial, the age of participants will be 18 years of age or older. Screening/Baseline will occur the same day to confirm the selection criteria for the study are met. Qualified participants in TCAAP-PH will be selected to receive TCA at this visit. Participants will administer TCA to the affected areas of the palms/fingers daily throughout the treatment period. This study is being conducted to evaluate the short-term safety and efficacy of TCA dosed up to 1 week of treatment duration. In addition to safety, another objective of this study is to evaluate short-term efficacy in this population. To evaluate the efficacy, response will be assessed based on the hyperhidrosis disease severity scale (HDSS), an instrument that is widely used to assess the severity of palmar hyperhidrosis by the subject that best reflects his or her experience with sweating of the specified body area. Participants are asked "How would you rate the severity of your hyperhidrosis?" (1) My sweating is never noticeable and never interferes with my daily activities (2) My sweating is tolerable but sometimes interferes with my daily activities (3) My sweating is barely tolerable and frequently interferes with my daily activities (4) My sweating is intolerable and always interferes with my daily activities. A score of 3 or 4 indicates severe hyperhidrosis. A score of 1 or 2 indicates mild or moderate hyperhidrosis. A 1-point improvement in HDSS score has been associated with a 50% reduction in sweat production and a 2-point improvement with an 80% reduction. This tool has been well accepted and used in multiple palmar hyperhidrosis clinical trials as a reliable and reproducible measure of palmar hyperhidrosis severity. In addition, gravimetric sweat production and grip strength measurements will be used to assess the short-term efficacy in this population. The total sample size for the study is estimated to be approximately 30 participants. The TCAAP-PH treatment protocol that is being administered to the study intervention group has been used for other indications (e.g. extraoral wound closures and skin protectants) with minimal risk to patients. Due to the low risk profile of cyanoacrylate, the use of this agent for palmar hyperhidrosis will be evaluated with no significant concern regarding the dosage that will be applied to the affected areas. Dosage is 100 µL once per day, which is sufficient to cover the palmar and phalangeal surface of both hands when properly applied. The solution will be applied in the morning after subjects complete their morning meal and washing routine. The end of the study is defined as the date of the last visit of the last participant in the study. The date of the last visit will be considered the Week 4 phone call.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
